• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events.

作者信息

Schulzer M, Mancini G B

机构信息

Department of Medicine, University of British Columbia, Vancouver, Canada.

出版信息

Int J Epidemiol. 1996 Aug;25(4):704-12. doi: 10.1093/ije/25.4.704.

DOI:10.1093/ije/25.4.704
PMID:8921446
Abstract

BACKGROUND

Common indices for the quantal assessment of treatment efficacy are reviewed. The absolute risk reduction is a practical index for public health considerations. Its reciprocal has been termed the 'Number Needed to Treat' (NNT), representing the health effort that must on average be expended to accomplish one tangible treatment target. We extend the NNT to evaluate outcome combinations of treatment benefits versus treatment harms.

METHODS

We describe the mathematical context of the NNT, and extend it to evaluate outcome combinations (treatment success/failure with/without treatment-induced adverse effects) in a treated population. These extensions are carried out assuming either independence or positive association between treatment benefit and treatment harm. A method is provided for calculating the standard errors of these extended NNT values. Applications to cost-effectiveness analysis are discussed.

RESULTS

We calculate NNT in three recent therapeutic studies. The results of a trial of the prevention of strokes with warfarin in patients with non-valvular atrial fibrillation are analysed to evaluate treatment success (stroke prevention) against treatment-induced bleeds. An NNT-related cost-benefit analysis is also carried out. We also analyse the results of a study of two modalities of chemotherapeutic treatment in small-cell lung cancer, and of two modalities of surgical intervention in the treatment of cholelithiasis.

CONCLUSIONS

The NNT are useful in direct evaluation of outcome-specific treatment benefits versus treatment-induced harms. They may also be used in cost-effectiveness analyses and are helpful in guiding public health programmes towards the identification of optimal treatment strategies.

摘要

相似文献

1
'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events.
Int J Epidemiol. 1996 Aug;25(4):704-12. doi: 10.1093/ije/25.4.704.
2
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.非维生素 K 口服抗凝剂与华法林用于房颤患者:绝对获益和危害评估带来新的见解。
Cardiovasc Ther. 2016 Apr;34(2):100-6. doi: 10.1111/1755-5922.12173.
3
Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine.
Circulation. 1999 Jan 26;99(3):377-83. doi: 10.1161/01.cir.99.3.377.
4
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.华法林与阿司匹林预防非瓣膜性心房颤动患者卒中的成本效益分析
JAMA. 1995 Dec 20;274(23):1839-45.
5
The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.美国针对心房颤动且有高卒中风险患者的抗凝管理服务的成本效益
Pharmacoeconomics. 2006;24(10):1021-33. doi: 10.2165/00019053-200624100-00009.
6
Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.阿哌沙班与华法林或阿司匹林用于心房颤动患者预防卒中的成本效益:希腊视角
Am J Cardiovasc Drugs. 2017 Apr;17(2):123-133. doi: 10.1007/s40256-016-0204-1.
7
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.法国心房颤动患者的卒中预防:新型口服抗凝剂(阿哌沙班、达比加群和利伐沙班)、华法林和阿司匹林的成本效果比较。
J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.
8
Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.阿哌沙班与华法林在中国非瓣膜性心房颤动患者中的成本效益:一项真实世界与模型分析
PLoS One. 2016 Jun 30;11(6):e0157129. doi: 10.1371/journal.pone.0157129. eCollection 2016.
9
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.希美加群用于慢性心房颤动患者卒中预防的成本与效果
JAMA. 2005 Feb 9;293(6):699-706. doi: 10.1001/jama.293.6.699.
10
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.达比加群酯与维生素K拮抗剂预防心房颤动患者卒中的成本效益分析:法国医保支付方视角
Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

引用本文的文献

1
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.设计非劣效性结核病治疗试验:确定具有可接受疗效的药物方案的实际优势。
PLoS Med. 2019 Jul 12;16(7):e1002850. doi: 10.1371/journal.pmed.1002850. eCollection 2019 Jul.
2
Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis.通过聚类分析对急性呼吸窘迫综合征患者不同生物学表型的识别与验证
Thorax. 2017 Oct;72(10):876-883. doi: 10.1136/thoraxjnl-2016-209719. Epub 2017 Apr 27.
3
Number Needed to Treat in Multiple Sclerosis Clinical Trials.
多发性硬化症临床试验中的治疗所需人数。
Neurol Ther. 2017 Jun;6(1):1-9. doi: 10.1007/s40120-017-0063-y. Epub 2017 Feb 7.
4
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.在 IIIB/C 期和 IVM1a 期黑色素瘤患者中,talimogene laherparepvec 与粒细胞巨噬细胞集落刺激因子的疗效和安全性比较:III 期 OPTiM 试验的亚组分析
Onco Targets Ther. 2016 Nov 16;9:7081-7093. doi: 10.2147/OTT.S115245. eCollection 2016.
5
Comparisons are odious.人比人气死人。
Perspect Clin Res. 2014 Oct;5(4):143-4. doi: 10.4103/2229-3485.140540.
6
A tool to balance benefit and harm when deciding about adjuvant therapy.
Br J Cancer. 2009 Mar 24;100(6):913-7. doi: 10.1038/sj.bjc.6604962.
7
New technologies in cancer and their assessment. The clinical surgeon's point of view.癌症领域的新技术及其评估。临床外科医生的观点。
Clin Transl Oncol. 2008 Nov;10(11):713-8. doi: 10.1007/s12094-008-0277-7.
8
Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.经风险调整的净疗效(NEAR):一种衡量风险 - 获益平衡的简单方法。
PLoS One. 2008;3(10):e3580. doi: 10.1371/journal.pone.0003580. Epub 2008 Oct 31.
9
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.在曲坦类药物治疗急性偏头痛的临床试验中使用持续无痛加无不良事件的终点指标。
CNS Drugs. 2007;21(1):73-82. doi: 10.2165/00023210-200721010-00006.